Aug 2026· Redox Biology· Vol 96, pp. 104350· 0 citations· 58 references
Medicine
TL;DR
Fibroblast-derived myocilin is identified as a fibroblast-derived mediator that drives cardiomyocyte mitochondrial dysfunction and ROS production in HF and a fibroblast–cardiomyocyte signaling axis in which myocilin disrupts cardiomyocyte metabolic homeostasis is identified.
Abstract
Heart failure (HF) remains a leading cause of morbidity and mortality worldwide. A hallmark of HF progression is profound metabolic remodeling accompanied by mitochondrial dysfunction in cardiomyocytes. Impaired mitochondrial oxidative phosphorylation, excessive reactive oxygen species (ROS) production, and disrupted redox homeostasis collectively drive oxidative damage and compromise mitochondrial integrity, ultimately leading to contractile failure, for which no viable strategies currently exist. Although mitochondrial dysfunction is now recognized as a central driver of HF pathogenesis, the upstream molecular regulators that initiate or amplify these defects remain incompletely understood. Here, we identify myocilin as a fibroblast-derived mediator that drives cardiomyocyte mitochondrial dysfunction and ROS production in HF. Myocilin was consistently upregulated in patients with HF and in murine HF models induced by transverse aortic constriction and isoproterenol, and was predominantly expressed in cardiac fibroblasts. In vivo study using male mice showed that myocilin overexpression exacerbated cardiac dysfunction and fibrosis, whereas genetic ablation markedly alleviated pathological remodeling. Using transwell systems and recombinant protein stimulation, we found that fibroblast-derived myocilin impaired mitochondrial function in cardiomyocytes, as evidenced by reduced ATP production, increased ROS, and loss of membrane potential. Mechanistically, myocilin directly interacted with SLC3A2, the heavy chain that pairs with SLC7A11 to form the cystine/glutamate antiporter, on cardiomyocytes and promoted its degradation, thereby impairing cystine uptake. This led to glutathione depletion and redox imbalance, subsequently triggering ferroptosis-associated mitochondrial dysfunction in cardiomyocytes. Collectively, these findings identify a fibroblast–cardiomyocyte signaling axis in which myocilin disrupts cardiomyocyte metabolic homeostasis. Targeting the myocilin–SLC3A2 pathway may represent a potential therapeutic strategy for HF.
Heart failure with preserved ejection fraction (HFpEF) is a heterogeneous and increasingly prevalent syndrome for which effective disease-modifying therapies remain limited, in part because its multicellular pathophysiology remains incompletely understood. Mitochondrial dysfunction has emerged as an important contribut...
Anupriya Sinha, Devin W. Kolmetzky, Dhanendra Tomar et al.· Redox Biology· 0 citations
Heart failure (HF) is a major cardiovascular syndrome with increasing global incidence and mortality rates. Cardiomyocyte injury and ventricular remodeling are central pathological processes driving HF progression. Although several forms of regulated cell death have been implicated in HF, the mechanisms underlying card...
Shu Ding, Yun-Ke Zang, Ya-Qi Li et al.· Frontiers in Cardiovascular...· 0 citations
Extensive mitochondrial remodeling occurs during heart failure with reduced ejection fraction (HFrEF), yielding either protective adaptations that mitigate dysfunction or detrimental alterations that accelerate disease progression. Central to this remodeling are maladaptive metabolic reprogramming, featured by aberrant...
Tau is classically defined as a microtubule-associated protein whose dysfunction underpins neurodegenerative disorders. However, its role in cardiac pathophysiology remains elusive despite recent evidence of its cardiac expression. Here, we report that a ~55 kDa Tau-immunoreactive species, which is commonly found in th...
Jing-Ping Xu, Yu-Jia Xing, Qi-Qi Liu et al.· International Journal of Mol...· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.